Cytochrome P450 Ω-hydroxylase Research Articles

Cytochrome p450 and vascular homeostasis.

Since the initial reports that renal cytochrome P450 (CYP) enzymes can metabolize arachidonic acid to substances which affect arterial tone, it has become increasingly clear that CYP enzymes expressed within the cardiovascular system play a crucial role in the modulation of vascular homeostasis. There is strong evidence suggesting that the activation of a CYP epoxygenase in endothelial cells is an essential step in nitric oxide and prostacyclin-independent vasodilatation of several vascular beds, particularly in the heart and kidney. A smooth muscle CYP omega-hydroxylase, on the other hand, generates a vasoconstrictor eicosanoid that is central to the myogenic response. Moreover, CYP epoxygenase and omega-hydroxylase products, as well as CYP-derived reactive oxygen species, are intracellular signal transduction molecules involved in several signaling cascades affecting numerous cellular processes, including vascular cell proliferation and angiogenesis. This review summarizes the vascular effects of epoxyeicosatrienoic acids and 20-hydroxyeicosatetraenoic acid, both of which are CYP-derived metabolites of arachidonic acid, endogenously generated within endothelial and vascular smooth muscle cells. Although the link between CYP expression/activity and cardiovascular disease is currently tentative, the evidence being accumulated to suggest that CYP pathways are altered in animal models of hypertension and atherosclerosis can no longer be ignored. The development of selective pharmacological tools is, however, a prerequisite for the analysis of the involvement of specific CYP isoforms in the regulation of vascular homeostasis in human subjects.

Cytochrome P-450 omega-hydroxylase: a potential O(2) sensor in rat arterioles and skeletal muscle cells.

The purposes of this study were to 1) further evaluate the possible role that vasoconstrictor metabolites of cytochrome P-450 (CYP) omega-hydroxylase plays in O(2)-induced constriction of arterioles in the rat skeletal muscle microcirculation, 2) determine whether omega-hydroxylases are expressed in rat cremaster muscle, and 3) determine whether the enzyme is located in the parenchyma or the arterioles. O(2)-induced constriction of third-order arterioles in the in situ cremaster muscle of Sprague-Dawley rats was significantly inhibited by the CYP inhibitors N-methyl-sulfonyl-12,12-dibromododec-11-enamide (DDMS; 50 microM) and 17-octadecynoic acid (ODYA; 10 microM). Immunoblot analysis with antibody raised against CYP4A protein indicated the presence of immunoreactive proteins in the cremaster muscle and in isolated arterioles and muscle fibers from this tissue. However, the molecular mass of the immunoreactive proteins was 85 kDa instead of the expected 50--52 kDa for CYP4A omega-hydroxylase isolated from rat liver or kidney. Treatment of the cremaster muscle with deglycosidases shifted the bands to the expected range which indicates that these proteins are likely glycosylated in skeletal muscle. Immunohistochemistry revealed intense staining of both muscle fibers and microvessels in the cremaster muscle. The results of this study indicate that O(2) sensing in the skeletal muscle microcirculation may be mediated by CYP4A omega-hydroxylases in both arterioles and parenchymal cells.

Differential Effect of Cytochrome P-450 ω-Hydroxylase Inhibition on O2-Induced Constriction of Arterioles in SHR With Early and Established Hypertension

Differential Effect of Cytochrome P-450 ω-Hydroxylase Inhibition on O₂-Induced Constriction of Arterioles in SHR With Early and Established Hypertension

Cytochrome P450 metabolites of arachidonic acid may be important mediators in angiotensin II-induced vasoconstriction in the rat mesentery in vivo

We have investigated the role of cytochrome P450 (CYP-450) metabolites of arachidonic acid in the modulation of vascular reactivity to angiotensin II in vivo using an in situ blood-perfused mesenteric preparation in anaesthetized spontaneously hypertensive rats (SHR). Miconazole, a non-selective inhibitor of CYP-450 that inhibits both hydroxylation and epoxidation, substantially suppressed mesenteric vasoconstrictor responses to angiotensin II in SHR, but had no effect on responses to noradrenaline or sympathetic nerve stimulation. In normotensive Wistar–Kyoto (WKY) rats, miconazole caused only a modest suppression of vasoconstrictor responses to angiotensin II. N-Methylsulphonyl-12,12-dibromododec-11-enamide (DDMS), a new selective inhibitor of CYP-450 ω-hydroxylase activity, decreased mean intra-arterial blood pressure and significantly attenuated mesenteric angiotensin II-induced vasoconstrictor responses in SHR. Isolated mesenteric vessels were able to metabolize 14C-labelled arachidonic acid to hydroxyeicosatetraenoic acids (HETEs) in vitro, and this was substantially inhibited by DDMS. The results from the present studies combined with the existing evidence that angiotensin II stimulates the release of 20-HETE, a CYP-450 metabolite of arachidonic acid, suggest that CYP-450-derived HETEs may be important mediators in angiotensin II-induced vasoconstriction. However, the development of more sensitive assays for the detection in vivo of 20-HETE in mesenteric vessels would be required to confirm these findings.

Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride.

Renal function is perturbed by inhibition of nitric oxide synthase (NOS). To probe the basis of this effect, we characterized the effects of nitric oxide (NO), a known suppressor of cytochrome P450 (CYP) enzymes, on metabolism of arachidonic acid (AA), the expression of omega-hydroxylase, and the efflux of 20-hydroxyeicosatetraenoic acid (20-HETE) from the isolated kidney. The capacity to convert [(14)C]AA to HETEs and epoxides (EETs) was greater in cortical microsomes than in medullary microsomes. Sodium nitroprusside (10-100 microM), an NO donor, inhibited renal microsomal conversion of [(14)C]AA to HETEs and EETs in a dose-dependent manner. 8-bromo cGMP (100 microM), the cell-permeable analogue of cGMP, did not affect conversion of [(14)C]AA. Inhibition of NOS with N(omega)-nitro-L-arginine-methyl ester (L-NAME) significantly increased conversion of [(14)C]AA to HETE and greatly increased the expression of omega-hydroxylase protein, but this treatment had only a modest effect on epoxygenase activity. L-NAME induced a 4-fold increase in renal efflux of 20-HETE, as did L-nitroarginine. Oral treatment with 2% sodium chloride (NaCl) for 7 days increased renal epoxygenase activity, both in the cortex and the medulla. In contrast, cortical omega-hydroxylase activity was reduced by treatment with 2% NaCl. Coadministration of L-NAME and 2% NaCl decreased conversion of [(14)C]AA to HETEs without affecting epoxygenase activity. Thus, inhibition of NOS increased omega-hydroxylase activity, CYP4A expression, and renal efflux of 20-HETE, whereas 2% NaCl stimulated epoxygenase activity.

Eicosanoid biosynthesis: differential inhibition of cytochrome P450 epoxygenase and ω-hydroxylase

Biphenyl 4 and vinyldibromide 8 were prepared on a multigram scale and shown to be comparatively specific arachidonic acid epoxygenase and ω-hydroxylase inhibitors, respectively, in rat kidney microsomal fractions. Biphenyl 4 and vinyldibromide 8 were prepared on a multigram scale and shown to be comparatively specific arachidonic acid epoxygenase and ω-hydroxylase inhibitors, respectively, in rat kidney microsomal fractions.

New group of lipid mediators containing omega-hydroxyarachadonic acid (20-HETE).

20-HETE is a biologically active product of arachidonic acid and cytochrome P450 ω-hydroxylase of the 4A gene family and is an abundant microsomal eicosanoid in the rat kidney.1 However, very little is known about factors controlling the biosynthesis and metabolic fate of 20-HETE in the kidney. Cyclooxygenase metabolizes 20-HETE into ω-OH-PGs, formation of which was proposed to explain the vasoconstrictor activity of 20-HETE in the kidney.2 Human platelets metabolize 20-HETE into a complex mixture of products of which 11,20-dihydroxyeicosatetraenoic acid (11,20-DiHETE), and 12,20-DiHETE are the major metabolites.3. We observed that the stimulation of the rat kidney with hormones or calcium ionophore results in an accumulation of 20-HETE, which is readily detectable by GC/MS.4, 5 The release of 20-HETE from renal slices stimulated by calcium ionophore cannot be inhibited with ETYA, which suggested to us that calcium influx is required for the release of 20-HETE. The isolated perfused kidney, challenged with angiotensin II (ang II) or endothelin-1, rapidly releases 20-HETE and often other CYP450 subterminal HETEs, into the perfusion fluid in amounts 5 to 10-fold higher relative to control levels. Brief stimulation of mTAL cells with ang II leads to a selective release of 20-HETE.6 These results suggested that 20-HETE could be released from renal tissue phospholipids via a receptor-mediated activation of phospholipase (PL)A2. In this study we obtained evidence that the release of 20-HETE from renal phospholipids is possible and represents a new component of ang II-dependent effects on renal function.